Nykode Therapeutics ASA (NYKD) - Total Liabilities

Latest as of September 2025: Nkr6.45 Million NOK ≈ $678.20K USD

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has total liabilities worth Nkr6.45 Million NOK (≈ $678.20K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Nykode Therapeutics ASA (NYKD) cash conversion ratio to assess how effectively this company generates cash.

Nykode Therapeutics ASA - Total Liabilities Trend (2016–2024)

This chart illustrates how Nykode Therapeutics ASA's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Nykode Therapeutics ASA's assets to evaluate the company's liquid asset resilience ratio.

Nykode Therapeutics ASA Competitors by Total Liabilities

The table below lists competitors of Nykode Therapeutics ASA ranked by their total liabilities.

Company	Country	Total Liabilities
Thuan Duc JSC VN:TDP	Vietnam	₫3.35 Trillion
Action Electronics Co Ltd TW:3024	Taiwan	NT$1.50 Billion
Currency Exchange International Corp TO:CXI	Canada	CA$37.52 Million
Yuken India Limited NSE:YUKEN	India	Rs2.56 Billion
Wielton S.A. WAR:WLT	Poland	zł1.61 Billion
Ramaco Resources Inc. NASDAQ:METCB	USA	$322.74 Million
Edel SE & Co. KGaA F:EDL	Germany	€162.51 Million
Crosswood PA:CROS	France	€16.46 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Nykode Therapeutics ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NYKD company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	170.98	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	16.37	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.06	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.01	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nykode Therapeutics ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nykode Therapeutics ASA (2016–2024)

The table below shows the annual total liabilities of Nykode Therapeutics ASA from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	Nkr17.27 Million ≈ $1.82 Million	-53.24%
2023-12-31	Nkr36.93 Million ≈ $3.89 Million	-42.71%
2022-12-31	Nkr64.46 Million ≈ $6.78 Million	-9.85%
2021-12-31	Nkr71.50 Million ≈ $7.52 Million	+39.71%
2020-12-31	Nkr51.18 Million ≈ $5.39 Million	+1.30%
2019-12-31	Nkr50.52 Million ≈ $5.32 Million	+280.83%
2018-12-31	Nkr13.27 Million ≈ $1.40 Million	+21.29%
2017-12-31	Nkr10.94 Million ≈ $1.15 Million	+528.02%
2016-12-31	Nkr1.74 Million ≈ $183.26K	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$110.82 Million

Nkr1.05 Billion NOK

Market Cap Rank

#18783 Global

#165 in Norway

Share Price

Nkr3.23

Change (1 day)

+5.74%

52-Week Range

Nkr1.47 - Nkr3.88

All Time High

Nkr91.25